A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination with LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors
Study of LY3321367 Alone or in Combination with LY3300054 in Patients with Solid Tumors
Sponsor: Eli Lilly
Enrolling: Male and Female Patients
IRB Number: AAAR5271
U.S. Govt. ID: NCT03099109
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The main purpose of this study is to learn more about the study drug called LY3321367. The study wants to know more about the following: The safety of LY3321367 alone and in combination with another drug called LY3300054 and any side effects you might have Whether LY3321367 is tolerable when taken alone and in combination with LY3300054. How much LY3321367 should be given to patients. Cancer types: breast cancer, lung cancer, gynecologic cancers, skin cancers, melanoma, prostate cancer.
This study is closed
Investigator
Mark Stein, MD
Do You Qualify?
Have you been diagnosed with solid tumor (listed above)? Yes No
Have you received treatment for your disease before? Yes No
Are you able to walk, care for yourself, and do light physical activities? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE